Nieuwsfeed
- How the FDA could save 2,700 clinical trials from becoming research waste
- Your weekly roundup of STAT's First Opinion
- Uitgelicht en gespot op internet (week 3, 2022)
- TrialSite News Daily Digest
- Weekend reads: Academic fraud factories; zombie science; ‘Silicon Valley’s new obsession’
- Weekend reads: Academic fraud factories; zombie science; ‘Silicon Valley’s new obsession’
- Why telehealth startups are steering clear of abortion pills
- TrialSite News Daily Digest
- What lured Hal Barron away?; Top FDA minds on accelerated approval reforms; ‘Dead wrong’ Aduhelm ad blitz; and more
- Webinar: Clinical trial results reporting on EudraCT made easy
- Know Your Treatment Options for COVID-19
- FDA Takes Actions to Expand Use of Treatment for Outpatients with Mild-to-Moderate COVID-19
- How the Biogen CEO could handle Medicare decision; pharma's latest hires and moves
- FDA Public Meeting: Identification of Concepts and Terminology for Multi-Component Biomarkers - 03/23/2022
- IBM’s Watson Health is sold off in parts; paying doctors to answer their emails
- COVID-19 Vaccine Safety Surveillance
- OraQuick ADVANCE Rapid HIV-1/2 Antibody Test
- Collecting and Providing 702(b) Portions of FDA Official Samples
- CDRH outlines plan to understand sex and gender differences in medical devices
- FDA Roundup: January 21, 2022
- Last Call: Ticket prices for the Breakthrough Science Summit increase tonight!
- COVID-19 therapeutics tracker
- Antimicrobial Resistance Information from FDA
- Critics push back on Alzheimer’s Association ad blitz to get Medicare to change its Aduhelm ruling: 'Dead wrong'
- Failing to confirm clinical benefit, Gilead pulls 2 accelerated approval indications for cancer drug
- Yingli Pharma brings small molecule research to the US in new pact with MD Anderson; UCB's psoriatic arthritis drug shows positive PhIII results
- FDA Voices
- BREAKING: IBM selling its Watson Health division
- Another day, another xenotransplant, as United Therapeutics looks to beat competitors to sci-fi-esque breakthrough
- 2022 Officers and New Member Announcement
- Biotech’s red tape, the latest billionaire science project, & a (possible) Omicron reprieve
- Time limits on accelerated approvals? FDA's oncology chief Rick Pazdur eyes potential reforms via international approaches
- Wat is de impact van de pandemie op wetenschap(pers)?
- German Regulators Publish Cookie Guidance
- Covid-19 roundup: HHS may struggle to absorb Operation Warp Speed; Europe has no plans for a fourth vaccine dose
- Merck wins legal battle over insurance coverage after ransomware attack
- Florida man convicted of falsifying clinical trial results sentenced to over 2 years in prison
- So what exactly does Verily do? A new deal with L'Oréal doesn't clear up much
- The RW Daily: Two abstracts about unapproved heart technology retracted. And "Why was a study about autism cited by a paper on plant beauty?"
- Questioning combination therapies, Biogen's dubious courage, & Califf on agency teamwork
- TrialSite News Daily Digest
- Two abstracts about unapproved heart technology retracted
- Wastewater lessons, 'saliva sharing' & paying doctors to answer emails
- Activision’s Roots and the Many Falls of Atari
- As Hal Barron steals the show, there’s no off position on the John Maraganore switch; Danny Bar-Zohar makes another leap forward at Merck KGaA
- IFAPP Today newsletter - January 2022
- Belgium: Regulator to impose fines for unreported clinical trials
- This Week at FDA: Generic drug approvals continue downward trend, new guidance on clinical trial diversity coming
- European Parliament endorses legislation bolstering EU’s ability to tackle shortages
- New insight into combination cancer treatments; biotech's red tape